Mendelson Daniel Newman has made a notable move by acquiring options to purchase shares in Champions Oncology, Inc. This acquisition, reported in a recent SEC filing, highlights Newman’s commitment to the company and may reflect a positive outlook on the oncology sector.

The transaction details indicate that Newman acquired options to purchase 20,291 shares of common stock at an exercise price of $4.76 per share. This transaction was executed on November 5, 2026, and is significant as it suggests a vested interest in the future performance of Champions Oncology.

Background

Champions Oncology, Inc. is a company focused on developing and providing technology solutions for personalized medicine in oncology. The company operates under the SIC classification of Biological Products (No Diagnostic Substances) [2836]. Recent filings show that Champions Oncology has undergone various name changes, with its most recent name change occurring in 2007 from Champions Biotechnology, Inc.

What the Filing Says

The SEC filing, accession number 0001628280-26-072275, details the acquisition of options by Mendelson Daniel Newman. It states, "The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2026, February 5, 2027, May 5, 2027 and August 5, 2027, respectively." This structured vesting schedule indicates a long-term commitment to the company.

Impact

This acquisition may affect various stakeholders, including investors and analysts monitoring Champions Oncology's performance. By acquiring these options, Newman signals confidence in the company’s direction and its potential for growth in the competitive oncology market.

What's Next

The filing does not say what happens next.